<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850886</url>
  </required_header>
  <id_info>
    <org_study_id>PHCL79</org_study_id>
    <nct_id>NCT03850886</nct_id>
  </id_info>
  <brief_title>Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of Niacinamide
      supplementation on clinical outcome of fatty liver patients having type II DM through
      measurement of the following before and after Niacinamide administration: Liver enzymes,
      Lipid profie, HOMA-IR, Oxidative stress markers and endothelial dysfunction marker. Fibroscan
      with CAP will be done at baseline and at the end of the trial. Also, Evaluation of quality of
      life of patients before and after Niacinamide administration using Chronic Liver Disease
      questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Actual">August 7, 2019</completion_date>
  <primary_completion_date type="Actual">August 7, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steatosis using Fibroscan with CAP</measure>
    <time_frame>3 months</time_frame>
    <description>using Fibroscan with CAP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adiponectin mesurement</measure>
    <time_frame>3 months</time_frame>
    <description>Endothelial dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malondialdehyde</measure>
    <time_frame>3 monthes</time_frame>
    <description>Oxidative stress marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>3 months</time_frame>
    <description>Insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT, AST</measure>
    <time_frame>3 months</time_frame>
    <description>Liver enzymes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL, cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Lipid markers</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Chronic Liver Disease Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>quality of measurement</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Niacinamide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niacinamide oral tablets as Nature's Life 1000 mg tablets once daily for 3 months diabetes management including metformin or Sulphonylurea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diabetes management including metformin or Sulphonylurea</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Niacinamide Oral Tablet</intervention_name>
    <description>Nature's Life Niacinamide 1000 mg</description>
    <arm_group_label>Niacinamide group</arm_group_label>
    <other_name>Nicotinamide</other_name>
    <other_name>Vitamin B3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidiabetic</intervention_name>
    <description>Metformin or Sulphonylurea</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Niacinamide group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Male or female outpatients age 18 to 70 years old. 2. The diagnosis of NAFLD will
             be established according to the appearance of fatty liver on US or elevated liver
             enzymes (&gt;1.5 times normal level).

        Exclusion Criteria:

          -  1. History of alcohol abuse (as defined by an average daily consumption of alcohol &gt;
             30 g/day in men and &gt; 20 g/day in women).

             2. Cirrhotic patients.

          -  Fibroscan result &gt; 12Kpa or as

          -  predicted from FIB 4 score &gt; 3.25

        FIB-4 = age (yr) * AST (IU/L)/platelet count (109/L) * ALT1/2 (IU/L) 3. Hyper /
        hypoparathyroidism. 4. Cancer. 5. Viral hepatitis. 6. Biliary disease. 7. Autoimmune
        hepatitis 8. Other causes of liver disease (hemochromatosis, Wilson's disease). 9.
        Participants who took antibiotics, probiotic supplements and/or hepatotoxic medicines
        (NSAIDs, Amiodarone and methotrexate) within 6 months before the start of the study and
        during the study.

        10. Ascetic patients and congestive heart failure patients will be excluded due to
        unreliability of Fibroscan results in them.

        11. Pregnancy and lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AlZahraa hospital</name>
      <address>
        <city>Cairo</city>
        <zip>02</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>January 18, 2020</last_update_submitted>
  <last_update_submitted_qc>January 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Rasha Roshdy Ibrahim El-kady</investigator_full_name>
    <investigator_title>Teaching assisstant at department clinical pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

